Glibenclamide - profile of efficacy and safety
Glibenclemide is the most effective drug among oral hypoglycemic ones. The efficacy of this drug is determined by its unique chemical structure thatcontains sulfonylurea, not only ring, but also benzamid group in the side chain. This provides the maximum affinity for SUR 1 on the betbeta-cell ATP-de...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Endocrinology Research Centre
2011-09-01
|
| Series: | Сахарный диабет |
| Subjects: | |
| Online Access: | https://www.dia-endojournals.ru/jour/article/view/6230 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850141193936044032 |
|---|---|
| author | Lyudmila Viktorovna Nedosugova |
| author_facet | Lyudmila Viktorovna Nedosugova |
| author_sort | Lyudmila Viktorovna Nedosugova |
| collection | DOAJ |
| description | Glibenclemide is the most effective drug among oral hypoglycemic ones. The efficacy of this drug is determined by its unique chemical structure thatcontains sulfonylurea, not only ring, but also benzamid group in the side chain. This provides the maximum affinity for SUR 1 on the betbeta-cell ATP-dependentK+ channels and ability to associate with SUR 2A cells in the peripheral tissues such as cardiomyocytes, smooth muscle cells of the vascular walland adipocytes. However, this feature can increase the risk of hypoglycemic states and have a negative effect on the cardiovascular system. We considerdata from clinical studies proving the efficacy and safety of the drug, which were based on evidence of long-term observations, and which demonstratedreduced risk of vascular complications of diabetes, compatibility with drugs of other groups, and possibility to use in elderand multimorbid patients. Glibenclamidewas evaluated by prestigious H.G. Creutzfeldt Drug Prize in 2010. It is the only SCI listed essential medicine of the World Health Organization. |
| format | Article |
| id | doaj-art-d187a8b113214c82bc6d5c2ecf323917 |
| institution | OA Journals |
| issn | 2072-0351 2072-0378 |
| language | English |
| publishDate | 2011-09-01 |
| publisher | Endocrinology Research Centre |
| record_format | Article |
| series | Сахарный диабет |
| spelling | doaj-art-d187a8b113214c82bc6d5c2ecf3239172025-08-20T02:29:31ZengEndocrinology Research CentreСахарный диабет2072-03512072-03782011-09-01143859010.14341/2072-0351-62306188Glibenclamide - profile of efficacy and safetyLyudmila Viktorovna Nedosugova0I.M.Sechenov First Moscow State Medical University, MoscowGlibenclemide is the most effective drug among oral hypoglycemic ones. The efficacy of this drug is determined by its unique chemical structure thatcontains sulfonylurea, not only ring, but also benzamid group in the side chain. This provides the maximum affinity for SUR 1 on the betbeta-cell ATP-dependentK+ channels and ability to associate with SUR 2A cells in the peripheral tissues such as cardiomyocytes, smooth muscle cells of the vascular walland adipocytes. However, this feature can increase the risk of hypoglycemic states and have a negative effect on the cardiovascular system. We considerdata from clinical studies proving the efficacy and safety of the drug, which were based on evidence of long-term observations, and which demonstratedreduced risk of vascular complications of diabetes, compatibility with drugs of other groups, and possibility to use in elderand multimorbid patients. Glibenclamidewas evaluated by prestigious H.G. Creutzfeldt Drug Prize in 2010. It is the only SCI listed essential medicine of the World Health Organization.https://www.dia-endojournals.ru/jour/article/view/6230type 2 diabetes treatmentinsulin secretionsulfonylurea receptor - surk + atp channelsischemic preconditioninghypoglycemia |
| spellingShingle | Lyudmila Viktorovna Nedosugova Glibenclamide - profile of efficacy and safety Сахарный диабет type 2 diabetes treatment insulin secretion sulfonylurea receptor - sur k + atp channels ischemic preconditioning hypoglycemia |
| title | Glibenclamide - profile of efficacy and safety |
| title_full | Glibenclamide - profile of efficacy and safety |
| title_fullStr | Glibenclamide - profile of efficacy and safety |
| title_full_unstemmed | Glibenclamide - profile of efficacy and safety |
| title_short | Glibenclamide - profile of efficacy and safety |
| title_sort | glibenclamide profile of efficacy and safety |
| topic | type 2 diabetes treatment insulin secretion sulfonylurea receptor - sur k + atp channels ischemic preconditioning hypoglycemia |
| url | https://www.dia-endojournals.ru/jour/article/view/6230 |
| work_keys_str_mv | AT lyudmilaviktorovnanedosugova glibenclamideprofileofefficacyandsafety |